Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VGT 309

Drug Profile

VGT 309

Alternative Names: VGT-309; VGT309 - Vergent Bioscience

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vergent Bioscience
  • Class Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Lung cancer

Most Recent Events

  • 28 Jan 2024 Updated efficacy and adverse events data from the phase II trial in Lung cancer released by Vergent Bioscience
  • 05 Oct 2023 Vergent Biosciences initiates a phase II VISUALIZE trial in Lung cancer (Diagnosis) in USA (IV) (NCT06145048)
  • 13 Sep 2023 Stanford University plans an early phase I trial for Colorectal cancer (IV, Infusion) in USA, in September 2023 (NCT06034197) (IRB-68096)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top